68Ga-DOTA-LM3

N/A

Report date: 2025/11/20 11:38:13

Base Information

Drug Name68Ga-DOTA-LM3

Drug Alias Name68Ga-DOTA-LM3

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesPeking Union Medical College

China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital

Inactive CompaniesN/A

Active IndicationsNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A